【24h】

Liposomal drug delivery systems--clinical applications.

机译:脂质体药物递送系统-临床应用。

获取原文
获取原文并翻译 | 示例
           

摘要

Liposomes have been widely investigated since 1970 as drug carriers for improving the delivery of therapeutic agents to specific sites in the body. As a result, numerous improvements have been made, thus making this technology potentially useful for the treatment of certain diseases in the clinics. The success of liposomes as drug carriers has been reflected in a number of liposome-based formulations, which are commercially available or are currently undergoing clinical trials. The current pharmaceutical preparations of liposome-based therapeutic systems mainly result from our understanding of lipid-drug interactions and liposome disposition mechanisms. The insight gained from clinical use of liposome drug delivery systems can now be integrated to design liposomes that can be targeted on tissues, cells or intracellular compartments with or without expression of target recognition molecules on liposome membranes. This review is mainly focused on the diseases that have attracted most attention with respect to liposomal drug delivery and have therefore yielded most progress, namely cancer, antibacterial and antifungal disorders. In addition, increased gene transfer efficiencies could be obtained by appropriate selection of the gene transfer vector and mode of delivery.
机译:自1970年以来,脂质体已被广泛用作药物载体,以改善治疗剂向体内特定部位的输送。结果,已经进行了许多改进,从而使得该技术潜在地可用于治疗诊所中的某些疾病。脂质体作为药物载体的成功已在许多基于脂质体的制剂中得到了反映,这些制剂可商购获得或正在接受临床试验。基于脂质体的治疗系统的当前药物制剂主要来自于我们对脂质-药物相互作用和脂质体处置机制的理解。现在可以整合从脂质体药物递送系统的临床使用中获得的见识,以设计可以靶向组织,细胞或细胞内区室的脂质体,无论是否在脂质体膜上表达靶标识别分子。这篇综述主要集中在脂质体药物输送方面引起最多关注的疾病,因此产生了最大的进展,即癌症,抗菌和抗真菌疾病。另外,通过适当选择基因转移载体和递送方式可以获得提高的基因转移效率。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号